Vivacta Bio
Summary active Updated Apr 30, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Vivacta Bio (Vivacta Biotechnology (Shanghai) Co., Ltd.) is a Shanghai-based biotechnology company developing in vivo CAR-T cell therapies for cancer and autoimmune diseases 12. The company was founded and is led by Dr. Liu Yarong 1. Its lead program, GT801, is a next-generation in vivo CAR-T therapy that has shown early clinical signal in hematologic malignancies and autoimmune conditions 12.
On April 29, 2026, Vivacta announced the close of Series A and Series A+ financing totaling over US$50 million 123. The Series A was led by Decheng Capital and the Series A+ was led by Loyal Valley Capital 12. Participating investors included OrbiMed, Hankang Capital, Eisai Innovation Inc., and C&D Emerging Industry Equity Investment, alongside existing shareholders Qiming Venture Partners, Beijing Shunxi, and Apricot Capital 12. Proceeds will fund GT801 clinical trials, regulatory submissions, research team expansion, and global operations 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-04-29 | Series A & A+ | $50M+ | Decheng Capital (A), Loyal Valley Capital (A+) | OrbiMed, Hankang Capital, Eisai Innovation Inc., C&D Emerging Industry Equity Investment, Qiming Venture Partners, Beijing Shunxi, Apricot Capital 12 |
What Investors Say
No independently sourced investor quotes found.
What Founders Say
No independently sourced founder quotes found.
Sources
-
PR Newswire, “Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million,” April 29, 2026, accessed April 2026. https://www.prnewswire.com/news-releases/vivacta-bio-closed-series-a-and-series-a-financing-of-over-us50-million-302756983.html↩↩↩↩↩↩↩↩
-
BioSpace, “Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million,” April 29, 2026, accessed April 2026. https://www.biospace.com/press-releases/vivacta-bio-closed-series-a-and-series-a-financing-of-over-us-50-million↩↩↩↩↩↩
-
FinSMEs, “Vivacta Bio Closes $50M Series A and Series A+ Financing,” April 2026, accessed April 2026. https://www.finsmes.com/2026/04/vivacta-bio-closes-series-a-and-series-a-financing.html↩